Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality that generates a significant burden on healthcare systems worldwide. [1] [2] Despite recent important progress in the understanding of the disease mechanisms and in treatment standardization, 2 episodes of severe exacerbations continue to be the major cause of unplanned hospitalizations in COPD patients, particularly in those with advanced disease stages. 3 This phenomenon, however, is also partly explained by the impact of commonly associated co-morbidities and poor social circumstances on COPD outcomes. 4 In view of the high social and economic burden generated by hospitalizations, new modalities of care aiming to decrease admissions through both patients' empowerment for self-detection of acute episodes 5, 6 and implementation of alternatives to conventional hospitalization have been developed in recent years. Short-stay units, respiratory day hospitals and home-based programs, such as home hospitalization (HH), are good examples of innovative services addressed to COPD patients.
It is largely accepted that HH is a safe and effective treatment modality for selected patients with COPD exacerbations. 7 The current view, however, is that HH schemes are only a suitable option in one out of four patients with severe exacerbations. This figure may be an underestimate because of rather strict inclusion criteria followed in the original randomized controlled trials considered in the Cochrane review alluded to above. 7 The majority of those trials excluded patients living alone as well as those with a partial pressure of oxygen in arterial blood Ͻ7.0 kPa. Further, these two criteria were adopted by NICE 8 recommending hospitalization of those patients with low PaO 2 on room air (Ͻ7 kPa) and insufficient social support.
We read with interest the courageous study by Khalid et al., 9 challenging whether patients with PaO 2 Ͻ7.0 kPa, living alone and both conditions together were exclusion criteria for HH. They retrospectively analysed a rather large group of HH patients with COPD clearly showing similar clinical outcomes between those with or without PaO 2 Ͻ7.0 kPa and also between COPD patients living alone and those having a carer. Moreover, these two conditions together (PaO 2 Ͻ7.0 kPa and living alone) did not seem to have a major influence on readmission rates. Clearly, a limitation of the study was the lack of statistical power to assess the effects of the above-mentioned two factors on mortality. Also the lack of information on clinical and functional characteristics of the patients assessed should be considered a limitation of the study. We take, however, two important messages from this paper. First, new modalities of care for chronic patients pertain to a relatively new area that needs continuous evaluation. Perhaps, it is too early to define clear-cut inclusion/ exclusion criteria for HH in some of these patients. A second message is that clinical guidelines should be taken as decision-support tools rather than strict rules constraining professional decisions, particularly when we analyse grey areas wherein strong scientific evidence has not been built-up yet. In fact, the physiological adaptability of human beings to chronically low PaO 2 is well known. The results reported by Khalid et al. 9 suggest that a given cut-off value for a low PaO 2 (i.e., Ͻ7.0 kPa) should be taken into account in the decisionmaking process, but it should not be considered an exclusion criterion for HH. Likely, what is relevant in terms of clinical impact is either a sudden decrease of PaO 2 during the acute episode or a lack of further improvement of arterial oxygenation after discharge.
Khalid's study also evaluated the impact of living alone on readmission rates. The influence of carers and the role of appropriate social support on clinical outcomes in chronic patients is widely accepted. One of the pivotal aspects of the Innovative Care for Chronic Conditions (ICCC) framework proposed by WHO 10 is to build proper interactions between healthcare and community services providing social support. In our experience, lack of appropriate social support is the second main cause of exclusions for HH -approximately 35% of eligible patients being severe comorbidities of the main exclusion factor. Again, the study by Khalid et al. 9 is likely stating that living alone might not be the right question, but the ability of the patient for self-management. Patient's independence to perform activities of daily living during an exacerbation, home adaptation to patient's needs, level of compliance and ability for self-administering therapy and the potential for an adequate communication of the patient with the specialized team are in our opinion some of the key aspects to be taken into account in the decision-making process.
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In summary, it is well accepted that HH programs are not suitable for all patients with severe COPD exacerbations. Some exclusion criteria rely on very strong grounds, namely: mental confusion, low arterial pH and so on, but it is clear that these new modalities of care for COPD patients require to be revisited before we are able to define proper clinical guidelines for chronic care. In this regard, the study conducted by Khalid et al. 9 represents a valuable contribution to the field. We must acknowledge, however, that a proper management of these patients will be only achieved when all building blocks of the ICCC framework will be in place.
